EWING, NJ, April 3, 2013 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the first
shipment of commercial-ready Vibex™ auto-injector devices to Teva at the end of the first quarter
2013. This initial order for pre-launch quantities of the generic epinephrine auto-injector represents
the first of many shipments that will take place during 2013.
Antares entered into an exclusive license development and supply agreement under which Teva is obligated to purchase all of its epinephrine auto-injector device requirements from us. We receive a negotiated purchase price for each device sold and will receive royalties on sales of their epinephrine product. On April 26, 2012, Antares announced a settlement agreement with Meridian Medical Technologies, a Pfizer subsidiary under which Teva may launch a generic epinephrine autoinjector on June 22, 2015 or earlier under certain circumstances, subject to approval from the U. S. Food and Drug Administration.